UF researchers discover first-of-its-kind compound to target lung cancer cells
Using an innovative technique, scientists discovered the first compound that effectively targets a protein that drives lung cancer.
All Posts
A vision for the next era of oncology clinical trials in the United States
Thomas George, M.D., FACP, FASCO, co-authored an AACI commentary on accelerating clinical trial activation.
$3.4 million NCI grant to advance stem cell-based breast cancer prevention
The study will explore how breast stem cells contribute to the early stages of breast tumor development.
Research Snapshot: Dietary supplement preserves muscle mass and strength lost in cancer, UF researchers find
Ursolic acid appeared to generate its beneficial effects in skeletal muscle by acting directly on muscle cells, the study found.
Propelling cancer drug discovery
UF Health Cancer Institute scientists are teaming up with experts at The Wertheim UF Scripps Institute to seek potential drug leads for many cancer types.
V Foundation Funds Sylvester-Led Strategy to Break Pancreatic Cancer Resistance
A new study published in JCI Insight identifies IL1RAP as an important driver of pancreatic cancer resistance and a promising therapeutic target.
Patient With Metastatic Melanoma Beats Cancer After Clinical Trial Treatment
For patients who do not respond as well to treatment, there are now new therapeutic options available, including innovative medications and highly promising clinical trials.
How Surviving Childhood Leukemia Shaped Amanda Talley’s Future
Amanda found a "godsend" in the UF Health Adult Cancer Survivorship Program, which has provided her support and care.
Tracking a Shape-Shifting Cancer: How IDH-Mutant Gliomas Evolve After Treatment
Sylvester Comprehensive Cancer Center researchers traced how IDH-mutant gliomas evolve after treatment.
Novel liquid biopsy test shows promise in monitoring treatment response for GI cancers
An ultra-sensitive liquid biopsy test that assesses DNA shed by tumors in the bloodstream may help doctors better monitor how patients with advanced gastrointestinal cancers respond to treatment.
